Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of procedures Merit’s portfolio supports. Acquisition projected to add approximately $18 million of revenue, on an annualized basis beginning in fiscal year 2026, with a mid-teens growth and accretive non-GAAP margin and profitability profile Merit reaffirms full-year 2025 […]

Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI

New BD FACSDiscover™ A8 Cell Analyzer Brings Leading-Edge Capabilities to Wider Range of Scientists across Academia and Biopharma

Visit ISMRM Booth H19 for Hands-On Demonstrations of the KyphoLift™ and KyphoWedge™ Systems

BioUtah president and CEO, Kelvyn Cullmore, recently penned an op-ed published in the Deseret News.

The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients.

In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months.

Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk